News
NeuralCure AI Expands AI Powered Medical Research and Diagnostics
- By John K. Waters
- 02/18/2025
NeuralCure AI, a healthcare technology company specializing in artificial intelligence-driven diagnostics and treatment simulations, announced Tuesday the launch of a new platform aimed at expediting medical research and personalized treatment development. The company also opened a fundraising round to expand its capabilities and partnerships.
The platform utilizes AI-driven simulations to test treatment protocols on digital models, commonly referred to as digital twins, to refine personalized healthcare strategies. The technology is designed to analyze medical imaging, genomic data, and environmental factors to aid in disease detection and treatment planning for conditions such as cancer, neurodegenerative diseases, and metabolic disorders.
"Our goal is to speed up the medical research process and improve treatment accuracy by running thousands of AI-powered simulations daily," said Orin Wilson, a spokesperson for NeuralCure AI, in a statement. "This allows us to refine treatment protocols more efficiently and integrate them into clinical research and patient care."
The company says its AI system aggregates various data sources, including medical imaging scans and neurological patterns, to identify potential treatment options more rapidly than conventional methods. It also assists healthcare providers in diagnosing diseases and evaluating different treatment pathways.
As part of its growth strategy, NeuralCure AI is seeking investment to scale its AI-powered research partnerships with hospitals, universities, and healthcare institutions. The funds will support further development of digital twin treatment models and the deployment of AI diagnostics into real-world clinical settings.
"We're not just predicting disease, we're engineering the fastest, most effective way to treat it," Wilson added. "By unlocking AI-driven precision medicine, we're making healthcare faster, smarter, and more accessible than ever before."
Early investor Ryan Doelling described the technology as an advancement in precision medicine, saying it has the potential to change the way diseases are diagnosed and treated.
About the Author
John K. Waters is the editor in chief of a number of Converge360.com sites, with a focus on high-end development, AI and future tech. He's been writing about cutting-edge technologies and culture of Silicon Valley for more than two decades, and he's written more than a dozen books. He also co-scripted the documentary film Silicon Valley: A 100 Year Renaissance, which aired on PBS. He can be reached at [email protected].